The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 407B. NVO holds the highest valuation in this group at 407B. The lowest valued company is PNEXF at 402.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 36%. SLNO experienced the highest price growth at 494%, while SEEL experienced the biggest fall at -82%.
The average weekly volume growth across all stocks in the Biotechnology Industry was 72%. For the same stocks of the Industry, the average monthly volume growth was 150% and the average quarterly volume growth was 108%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)